Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on May 27, 2025
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors
GlobeNewswire
·
May 27, 2025
LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient …
Forte Medical Revolutionises Women’s Routine Health with Peezy Midstream
GlobeNewswire
·
May 27, 2025
LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Forte Medical, the UK’s leading specialist in urine collection technology, today announces the launch of new Peezy Midstream. This pioneering device transforms routine urinary tract infection (UTI) and antenatal …
VIVUS Announces QSYMIA® Now Available at Costco Pharmacies Nationwide
GlobeNewswire
·
May 27, 2025
— Expanded retail access aims to enhance overweight or obesity treatment accessibility CAMPBELL, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that …
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
GlobeNewswire
·
May 27, 2025
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under …
Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
GlobeNewswire
·
May 27, 2025
Hamilton, May 27, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negotiate licensing agreement Altamira Therapeutics Ltd. (“Altamira” or the …
HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC
GlobeNewswire
·
May 27, 2025
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the successful completion of the dose escalation portion of its …
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 27, 2025
TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous …
AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders
GlobeNewswire
·
May 27, 2025
Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events in participants with mild or moderate Parkinson’s disease (PD) through 18 months post-gene transfer Non-motor assessments …
Leo International leaps from Lion City to Frankfurt with AI precision health listing
GlobeNewswire
·
May 27, 2025
SINGAPORE, May 27, 2025 (GLOBE NEWSWIRE) -- In a landmark announcement that bridges Asia and Europe, Leo International Group has acquired a controlling stake in SPOABG AG, a publicly listed company on the Frankfurt Stock Exchange (FSE). The company has now …
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), …
Court Denies Renovaro Motion for an Expedited Trial in July
GlobeNewswire
·
May 27, 2025
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the …
Iolyx Therapeutics Announces Phase 2 Results for ILYX-002 in Autoimmune Dry Eye Disease
GlobeNewswire
·
May 27, 2025
Results shared during a R…
SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System
GlobeNewswire
·
May 27, 2025
FORT LAUDERDALE, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and …
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
GlobeNewswire
·
May 27, 2025
BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseases BD9 designed using Biolojic’s Multibody Platform, which generates Antibodies capable of addressing multiple disease targets Collaboration builds on …
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
GlobeNewswire
·
May 27, 2025
REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with …
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis
GlobeNewswire
·
May 27, 2025
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “ …
Strongline returns to market, signs deal with QLog to ensure leading staff duress offering is available to health systems around the country
GlobeNewswire
·
May 27, 2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- Commure announced today a strategic partnership and licensing agreement with QLog, a leading Israeli innovator in real-time location systems (RTLS) and Bluetooth Low Energy (BLE) technologies for healthcare. …
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO …
BioNTech präsentiert auf der ASCO-Jahrestagung 2025 Fortschritte aus der diversifizierten Onkologie-Pipeline
GlobeNewswire
·
May 27, 2025
MAINZ, Deutschland, 27. Mai 2025 -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 30. Mai bis 3. Juni 2025 in Chicago, Illinois, stattfindet, klinische …
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
GlobeNewswire
·
May 27, 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’ …